ClinicalTrials.gg
Drug

Remimazolam clinical trials

Also written CNS7056.

Includes 47 studies of Remimazolam besilate and 23 studies of Remimazolam tosylate.

studies test it
214
open now
79
in phase 3
27
first study started
2009

How each study uses remimazolam is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the remimazolam studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
2 Jul 2020 · BYFAVO · NDA 212295 (FDA, Drugs@FDA; as remimazolam besilate)
European Union
26 Mar 2021 · Byfavo · EMEA/H/C/005246 (EMA; as remimazolam besilate)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Remimazolam
125
Byfavo
12
remimazolam group
10
Remimazolam besylate
6
Experimental
2

Development codes

CNS7056
8

In one entry with another drug

Given together, or one or the other

Esketamine and remimazolam
2

Studies by the year they started

213 studies that test it; most in 2022 (44); 1 more planned to start later

Studies that test remimazolam, by start year
YearStudies
20091
20101
20133
20142
20156
20161
20174
20182
20191
20202
202122
202244
202341
202423
202531
202629

By phase

A phase 1/2 study counts in both.

Early Phase 1
3
Phase 1
13
Phase 2
18
Phase 3
27
Phase 4
70
No phase
87

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 31 · Other 183

Jiangsu HengRui Medicine Co., Ltd. (14) · Seoul National University Hospital (13) · Paion UK Ltd. (13) · Tongji Hospital (9) · Yonsei University (8) · Asan Medical Center (6) · Second Affiliated Hospital of Wenzhou Medical University (6) · Pusan National University Yangsan Hospital (5)

Often tested with

Tested in the same studies.

Propofol (22) · Esketamine (5) · Flumazenil (5) · Ciprofol (4) · Dexmedetomidine (4) · Midazolam (3) · Remifentanil (2) · Etomidate (2)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 28, 3 in phase 3

Studies that test remimazolam, phase 3 first.

Studies

Open first, then newest update. How each study uses remimazolam is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 214

See all 214 studies that test remimazolam →

Given beside what is tested · 7 — remimazolam is usual care or a partner of the new treatment
As the comparator · 8 — what is tested is compared with remimazolam

Codes

What other systems call remimazolam · ClinicalTrials.gg INT005144

  • MeSH (NLM) C522201remimazolamOne source NLM
  • UNII (FDA) 7V4A8U16MBREMIMAZOLAMConfirmed FDA, NLM
  • RxNorm 2383941One source FDA
  • NCI Thesaurus C152187RemimazolamOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.